Company*
(Country;
Symbol)

Company*
(Country;
Symbol)

Product

Terms/Details (Date)


Angel
Biotechnology*
(UK)

Nautilus Biotech* (France)

Angel will manufacture Nautilus' interferon alpha drug Belerofon for Phase I trials

Terms of the deal were not disclosed (12/6)

Argenta
Discovery Ltd.*
(UK)

TTP LabTech Ltd.* (UK)

They launched a high-content assay development and screening service

The offering for drug discovery will be promoted by both companies (1/24)

Artes
Biotechnology
GmbH*
(Germany)

Proteo Biotech AG* (Germany)

Artes will manufacture Proteo's Elafin, a product for cardiovascular conditions

Artes licensed use of the yeast strain Hansenula polymorpha for use as an expression system (12/6)

ArtisOptimus
Inc.*

Taconic Farms Inc.*

Deal to bring a collection of primary mouse embryonic fibroblasts to the research community

ArtisOptimus will produce and distribute MEFs made from knockout mouse models to which Taconic holds exclusive rights; ArtisOptimus also licensed specific models (2/9)

Biogen Idec
Inc.
(BIIB)

Tanox Inc. (TNOX)

Tanox leased a biologics equipment and furniture and fixtures; the manufacturing facility in San Diego and acquired certain assets to expand antibody production capacity

Tanox is paying $5.5M for manufacturing lease runs through October 2011, with two five-year extension options (12/15)

Cobra Bio-
manufacturing
plc
(UK;LSE:CBF)

Oncolytics Biotech Inc. (Canada; ONCY)

Extended deal under which Cobra will manufacture and supply Reolysin

The manufacturing deal on the human reo- virus-based product is worth more than $1.4M to Cobra in 2005 (2/8)

GenOway SA*
(France)

Charles River Laboratories Inc. (NYSE:CRL)

Collaboration to supply genetically modified research models in Europe

Three-year deal under which Charles River will market and promote GenOway products to its European Transgenic Services customers (11/23)

Illumina Inc.
(ILMN)

Invitrogen Corp. (IVGN)

Deal to expand Illumina's Oligator DNA synthesis tech- nology and combine it with Invitrogen's marketing expertise

Invitrogen will invest $3.4M in Illumina's San Diego facility, and begin taking over marketing responsibilities (12/20)

Inyx Inc.
(OTC BB:IYXI)

NovaDel Pharma Inc. (AMEX:NVD)

Five-year deal under which Inyx will produce NovaDel's nitroglycerin lingual spray

The manufacturing contract is exclusive the first five years and nonexclusive the following five years (11/23)

LION
Bioscience AG
(Germany; FSE:LIOG)

BioBase GmbH* (Germany)

Collaboration to integrate BioBase's network content into LION's software products

Terms of the deal were not disclosed (2/10)

Stratagene
Corp.
(STGN)

Affymetrix Inc. (AFFX)

Stratagene will provide Affymetrix customers with new software solutions for GeneChip data analysis

Stratagene will develop a statistical analysis solution of Affymetrix gene expression microarrays under the nonexclusive deal (2/7)

SuperArray
Bioscience
Corp.*

Eurogentec SA* (Belgium)

They entered a deal on Super- Array's cDNA GEArray DNA microarray platform

Eurogentec got rights to repackage the products and sell them in Europe (11/22)

Tm Bioscience
Corp.
(Canada; TSE:TMC)

Gamidor Diagnostics* (Israel)

Gamidor will distrubute the Tag-It menu of genetic tests in Israel for three years

The exclusive distribution deal can be extended annually; terms of the deal were not disclosed (11/29)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments